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CObjectives: To estimate and assess the psychometric properties of a
multiattribute utility function (MAUF) for the Spanish version of the Tol-
erability and Quality of Life (TooL questionnaire). Methods: Balanced
ata on 243 patients diagnosed with schizophrenia or bipolar disorder
ere gathered. In addition to the demographic and clinical variables
nd the usual generic health-related quality of life (HRQoL) question-
aires (EuroQol-5D [EQ-5D] and Short Form-6D [SF-6D]), instruments
onsidered included the Spanish versions of the Positive and Negative
ymptoms of Schizophrenia Scale (PANSS), Young Mania Rating Scale
YMRS), Montgomery-Asberg Depression Rating Scale (MADRS), Udvalg
or Kliniske Undersogelser (UKU), and Clinical Global Impression Se-
erity (CGIS) scale. MAUF parameters estimation involved a number of
isual analogue scale (VAS) and time trade-off (TTO) ratings that proved
ifficult to be performed by the patients. After checking for inconsisten-
ies in patient responses, the original sample was reduced to a still bal-
nced subsample of 70 individuals. A multiplicative-form MAUF was es-
imated following the standard methodology. Results: Good convergent O
es Re
al So
oi:10.1016/j.jval.2010.11.016alidity was demonstrated because utility estimates from the MAUF pre-
ented strong correlations with utilities from the generic HRQoL instru-
ents included: SF-6D (0.66,P0.01), EQ-5D (0.69,P0.01), andmoderate
orrelations with the rest of instruments considered: PANSS (0.27, P 
.10), YMRS (0.30, P  0.08), MADRS (0.48, P  0.01), UKU (0.35, P 
.01). Criterion validitywas alsomet because differences inmean utilities
y clinical severitywere found (P 0.01). Utilities from theMAUF covered
wider range of health states [0.04,1.00] than those from the SF-6D
0.53,1.00] and EQ-5D [0.23,0.96]. Conclusions: Utilities from the MAUF
howed good psychometric properties, serving as a complement to
eneric health utilities. If misapplied, however, utilities from this in-
trument might favor the positive evaluation of drugs showing fewer
ssociated side effects.
eywords: bipolar disorder, multiattribute utility function, schizophre-
ia, specific health-related utilities.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Schizophrenia and bipolar disorder are severe and prevalent
worldwide mental syndromes affecting patient cognition, percep-
tion, and emotional function [1]. In Spain, the health-care costs
ssociated with schizophrenia account for 2.7% of the total public
ealth-care expenditure [2]. New antipsychotic drugs have proved
useful in reducing both relapses and severity of symptoms [3]. The
adverse effects of antipsychotic drugs, however, directly influence
patient health-related quality of life (HRQoL) [4] and might also
affect their adherence to treatment. Antipsychotic drugrelated
sexual dysfunction was recently linked, for instance, to poor com-
pliance in 36% ofmales and 20% of females diagnosedwith schizo-
phrenia [5].
Health status preference-based utility weights are derived
from either generic or specific HRQoL instruments by using differ-
ent techniques. The choice of whether to elicit utilities directly
from patients or from the general population is controversial [6].
Patients have direct experiencewith the disease and are likely able
to give a more informed response as to the burden of the health
states that they experience [4]. Yet not many studies have so far
* Address correspondence to: Guillermo Villa, BAP Health Outcom
E-mail: guillermo@baphealth.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.focused on the specific impact of the adverse effects of antipsy-
chotic drugs on patient preferences.
The purpose of this study was to develop a multiattribute
utility function (MAUF) to assess the impact of the adverse ef-
fects of antipsychotic drugs on patient health utilities. Multiat-
tribute utility theory (MAUT) [7,8] involves the development of
utility functions that account for preference interactions among
several health domains. Interestingly, MAUT allows the estima-
tion of utility scores for a large number of health states defined
from combining the items of a given instrument. With this ap-
proach, each subject has only to rate a subset of all possible health
states, making estimation possible in practice.
Based on a new specific health state classification system for
patients diagnosed with schizophrenia or bipolar disorder, the
Spanish version of the Tolerability and Quality of Life (TooL) ques-
tionnaire, a multiplicative-form MAUF is estimated and validated
against other instruments. The TooL questionnaire evaluates the
impact of the adverse effects of antipsychotic drugs on patient
HRQoL. The instrument was originally developed in Sweden [9,10]
and was recently adapted and validated in Spain [11–13], showing
adequate psychometric properties (i.e., feasibility; construct [uni-
search, Azcárraga, 12 A, 33010, Oviedo, Asturias, Spain.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
c
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565V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 6 4 – 5 7 0dimensionality], convergent and criterion validity; and test-retest
reliability).
Methods
The TooL questionnaire
The TooL questionnaire [9,10] was developed by an expert panel of
four Swedish psychiatrists experienced in the treatment of schizo-
phrenia and schizoaffective and bipolar disorders. First, the poten-
tially relevant domains from the existingHRQoL instrumentswere
identified. The five domains from the EuroQol-5D (EQ-5D) ques-
tionnaire were considered as well as specific domains from the
side effects commonly associated with antipsychotic medication.
After several rounds of discussion, the instrument was shortened
to include only eight domains reflecting different aspects of pa-
tient well-being, including functional aspects, general well-being,
and symptoms frequently reported by patients on antipsychotic
therapy. The Spanish version of the TooL questionnaire [11–13]
was also evaluated by a panel of clinicians and patients as part of
the process of cultural adaptation and validation.
Domains considered in the TooL questionnaire include (Table
1) anxiety and depression, usual activities, fatigue or weakness,
Table 1 – The TooL questionnaire (nonvalidated translation
Anxiety and depression (TooL1)
1. I do not feel anxious or depressed
2. I feel a little anxious or depressed
3. I feel rather anxious or depressed
4. I feel very anxious or depressed
Function capabilities (TooL2)
1. I have no difficulties with my usual activities
2. I have some difficulties with my usual activities
3. I have quite a lot of difficulty with my usual activities
4. I have great difficulties with my usual activities
Fatigue or weakness (TooL3)
1. I do not feel tired or weak
2. I feel a little tired or weak
3. I feel quite tired or weak
4. I feel very tired or weak
Body weight (TooL4)
1. I am not overweight
2. I am a little overweight
3. I am a quite a bit overweight
4. I am very overweight
Table 2 – Description of the health states considered.
Health state TooL1 TooL2 TooL3
A 4 1 1
B 1 4 1
C 1 1 4
D 1 1 1
E 1 1 1
F 1 1 1
G 1 1 1
H 1 1 1
J1 1 2 2
J2 4 1 4
P 1 1 1
W 4 4 4body weight, stiffness and tremor, bodily restlessness, sexual
function, and dizziness or nausea. Four levels (1 to 4) are pre-
sented within each attribute. The TooL score is obtained by
adding up the scores of the individual attributes. The higher the
TooL score is, the greater the impact of adverse effects on pa-
tient reported HRQoL. A total of 65,536 (48) specific health states
an be defined by combining the items and levels from the TooL
uestionnaire.
Multiattribute utility theory
As stated previously, a total of 65,536 health states can be de-
scribed by combining the items from the TooL questionnaire. This
fact makes direct utility assessment impractical because provid-
ing accurate utility ratings for each of those 65,536 states would
require drawing a very large sample. Under the MAUT approach,
this task is performed by only directly rating a carefully chosen
subset of all possible health states.
Three fundamental specifications of MAUFs have been de-
scribed in the literature [7,8]: linear-additive, multiplicative, and
multilinear. The first specification assumes no preference inter-
actions among the health domains considered. In the multipli-
cative form, domains can interact and are considered as either
preference substitutes or complements. The additive model is
o English).
Stiffness and tremor (TooL5)
1. I have no problems with stiffness or tremor
2. I have some problems with stiffness or tremor
3. I have quite a few problems with stiffness or tremor
4. I have great problems with stiffness or tremor
Bodily restlessness (TooL6)
1. I feel no bodily restlessness
2. I feel some bodily restlessness
3. I feel quite a lot of bodily restlessness
4. I feel a lot of bodily restlessness
Sexual function (TooL7)
1. I have normal sexual lust and ability
2. I have somewhat reduced sexual lust and ability
3. I have very reduced sexual lust and ability
4. I have no sexual lust or ability
Dizziness or nausea (TooL8)
1. I have no problems with dizziness or nausea
2. I have some problems with dizziness or nausea
3. I have rather a lots of problems with dizziness or nausea
4. I have great problems with dizziness or nausea
oL4 TooL5 TooL6 TooL7 TooL8
1 1 1 1 1
1 1 1 1 1
1 1 1 1 1
4 1 1 1 1
1 4 1 1 1
1 1 4 1 1
1 1 1 4 1
1 1 1 1 4
1 1 3 1 4
4 4 4 1 4
1 1 1 1 1intTo4 4 4 4 4
Scale
566 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 6 4 – 5 7 0therefore a special case of the multiplicative one, but the first
one assumes that attributes are neither substitutes nor comple-
ments. Finally, the multilinear specification allows for several
types of preference interactions. As a general advice, when
more than four health domains are to be considered, the rea-
sonable specifications to select are either the additive or the
multiplicative ones. The multiplicative-form MAUF, however,
has the strongest empirical support and its estimation proce-
dure is relatively simple [7,8].
The procedure for obtaining the coefficients of aMAUF consists
of several steps. In the first step, single-attribute utility functions
(SAUFs) are obtained for each attribute and level (considering that
the rest of attributes remain constant). In the second step, the
utility of each corner state, i.e., a state with one attribute at its
lowest level and the rest of the attributes at their highest level, is
estimated. Third, the estimates from steps 1 and 2 are then com-
bined to obtain the MAUF coefficients. These steps are explained
in detail.
In our particular case, each patient provided the following eval-
uations (Table 2 shows a description of the health states consid-
ered):
y Visual analogue scale (VAS) evaluations of each single attribute
(TooL1 to TooL8) and level, anchoring the best (takes on value
Table 3 – Descriptive statistics.
Analysis subsample
n % Mean SD
Age 69 41.88 11.09
Male 44 63.77
Female 25 36.23
Schizophrenia 36 52.17
Bipolar disorder 33 47.83
CGIS score 70 3.36 1.18
TooL score 69 13.81 3.28
TooL MAUF utilities 69 0.41 0.23
SF-6D utilities 70 0.74 0.11
EQ-5D utilities 65 0.81 0.15
PANSS score 38 62.08 16.26
YMRS score 36 5.28 5.73
MADRS score 70 10.99 7.23
UKU score 50 7.40 5.79
CGIS, Clinical Global Impression Severity; EQ-5D, EuroQol-5D; MAD
utility function; PANSS, Positive and Negative Symptoms of Schizop
UKU, Udvalg for Kliniske Undersogelser; YMRS, Young Mania Rating
Table 4 – Single-attribute value and utility functions.
Single-attribu
A B C D
100.00 100.00 100.00 100.00
72.84 70.00 74.83 70.97
32.00 27.30 30.49 31.11
0.00 0.00 0.00 0.00
Single-attribu
A B C D
1.00 1.00 1.00 1.00
0.70 0.67 0.72 0.68
0.30 0.25 0.28 0.29
0.00 0.00 0.00 0.00100) and the worst (takes on value 0) levels of each attribute. A
total of 16 VAS evaluations are then required in this task.
y VAS evaluations of the corner states (A to H), the marker or
intermediate states (J1 and J2), and the perfect health (P) and
the worst possible state (W). Twelve additional VAS evalua-
tions need to be therefore completed in this second task.
y Time Trade-Off (TTO) ratings of corner states A and F and
marker states J1 and J2, previously rated by VAS, to estimate
the alpha coefficient in an exponential function. In the TTO
rating task, patients had to compare all four health states to
perfect health in a 20, 25, 30, 35, and 40 years time frame. A
total of four TTO ratings are thus necessary.
A so-called mean-person utility approach is used for the esti-
mation of a common utility function for all respondents. This en-
tails calculating the mean VAS and TTO ratings across all the pa-
tients and then constructing a utility function based on these
mean ratings.
Marker states J1 and J2 were chosen to span the space between
perfect health and the worst possible state. They potentially en-
hance the precision when estimating the power function. Addi-
tionally, the marker states selected are directly comparable to
someof the corner states included and, therefore, they can beused
to check for preference reversals in the data.
Patients excluded
n % Mean SD P value (test)
171 41.82 10.89 0.97 (Student t)
108 62.79 0.89 (2)
64 37.21
85 49.13 0.67 (2)
88 50.87
173 3.40 1.18 0.88 (Mann-Whitney)
169 13.31 3.47 0.13 (Mann-Whitney)
171 0.74 0.11 0.89 (Student t)
152 0.84 0.14 0.20 (Student t)
94 67.51 25.19 0.38 (Mann-Whitney)
87 5.59 7.09 0.97 (Mann-Whitney)
166 11.36 8.31 0.94 (Mann-Whitney)
126 6.58 6.05 0.15 (Mann-Whitney)
ontgomery-Asberg Depression Rating Scale; MAUF, multiattribute
a Scale; SF-6D, Short Form-6D; TooL, Tolerability and Quality of Life;
.
lue functions
E F G H
100.00 100.00 100.00 100.00
67.91 72.73 69.06 72.64
27.87 30.09 25.04 30.51
0.00 0.00 0.00 0.00
ility functions
E F G H
1.00 1.00 1.00 1.00
0.65 0.70 0.66 0.70
0.26 0.28 0.23 0.29RS, M
hrenite va
te ut0.00 0.00 0.00 0.00
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attribute health state described by eight domains is as follows:
u
1
k
· 
j1
8
1 k · kj ·uj 1, k 0 (1)
where u is the utility associated with amultiattribute health state,
which is described by combining eight individual attributes; uj is
he SAUF for attribute j; k captures all possible interactions among
attributes; and kj represents the importance of attribute j when
determining the utility associated with a specific health state.
k and kj are parameters of the model and need to be estimated.
hen k is positive, the attributes are all preference complements.
omplementarities among attributes mean that, for instance, the
oint loss of capacity in two attributes would not be as bad as the
um of individual losses. When k is negative, the attributes are all
reference substitutes. If k  0, then the additive model holds.
The general approach for fitting a multiplicative-formMAUF is
escribed below in the disutility formulation. Disutility is just the
omplementary of the utility (1-u). The model was estimated in
isutility terms because the disutility corner states are easier to
magine and discriminate than are the utility corner states.
u
1
c
· 
j1
8
1 c · cj · 1uj 1, c 0 (2)
To estimate cj parameters, at least eight health states must be
pecified. Those health states must be selected in such a way that
akes estimation feasible. Also, they should be as imaginable and
ealistic as possible. Usually, the easiest way to select those health
Table 5 – Estimated utilities and VAS and TTO ratings
for the multiattribute health states.
Health
state
n VAS
rating
TTO
rating
Estimated
utility
A 70 56.30 0.47 0.53
B 70 51.50 0.49
C 70 54.47 0.52
D 70 57.24 0.54
E 70 52.93 0.50
F 70 52.77 0.50 0.50
G 70 55.61 0.53
H 70 61.04 0.58
J1 70 45.00 0.48 0.42
J2 70 26.39 0.35 0.25
P 70 95.71 0.95
W 70 8.30 0.08
alpha 0.92
TTO, time trade-off; VAS, visual analogue scale.
Table 6 – Multiattribute uility function coefficients.
Level Anxiety and depression Fatigue or w
1 1.00 1.00
2 0.86 0.87
3 0.68 0.66
4 0.54 0.52
Level Function capabilities Body weigh
1 1.00 1.00
2 0.83 0.85
3 0.62 0.68
4 0.49 0.55tates is to select the corner states. As stated, corner states are states
nwhich one attribute at a time is set to itsworst level, while the rest
f the attributes remainat their highest level. Theadvantageof using
he corner states is that the solution becomes immediate because cj
estimate is given directly by the disutility of the corner state associ-
ated with that attribute.
Once all cj parameters have been determined, the value of c can
e found by numerically solving:
 c 
j1
8
1 c · cj (3)
Value ratings need to be converted into utilities. Some au-
thors [7,8] suggest converting values into utilities by means of
an exponential utility function estimated from the data. For the
estimation of the function, each patient is usually asked to rate
a few health states by the Standard Gamble or TTO methods. In
our particular case, each patient is asked to rate four health
states from the TooL questionnaire by using both the VAS and
TTO methods. TTO (utilities, u) and VAS (values, v) ratings are
assumed to follow an exponential relationship:
u  1 1v (4)
he exponential utility function can be easily linearized, so that it
s possible to estimate alpha coefficient just by fitting the following
imple regression:
n1ui · ln1 vi ei (5)
ess Stiffness and tremor Sexual function
1.00 1.00
0.83 0.84
0.63 0.64
0.50 0.53
Bodily restlessness Dizziness or nausea
1.00 1.00
0.85 0.87
0.64 0.70
Table 7 – Spearman correlations.
TooL
utilities
SF-6D
utilities
EQ-5D
utilities
SF-6D utilities 0.66
P value 0.01
EQ-5D utilities 0.69 0.71
P value 0.01 0.01
PANSS score 0.27 0.45 0.38
P value 0.10 0.01 0.02
YMRS score 0.30 0.05 0.49
P value 0.08 0.76 0.01
MADRS score 0.48 0.59 0.44
P value 0.01 0.01 0.01
UKU score 0.35 0.29 0.30
P value 0.01 0.02 0.02
EQ-5D, EuroQol-5D; MADRS, Montgomery-Asberg Depression Rat-
ing Scale; PANSS, Positive and Negative Symptoms of Schizophre-
nia Scale; SF-6D, Short Form-6D; TooL, Tolerability and Quality of
Life; UKU, Udvalg for Kliniske Undersogelser; YMRS, Young Mania
Rating Scale.eakn
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568 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 6 4 – 5 7 0Now, all values (VAS evaluations) can be transformed into utilities.
Different approaches have been described to estimate alpha coef-
ficient. Mean or median utilities are usually regressed against
mean or median values, which supposes estimating the alpha co-
efficient using a reduced number of data points (just four points, in
our particular case).
Once parameters c and cj of the model have been estimated, the
multiplicative-formMAUF can be easily computed using Equation 2.
To evaluate the properties of the estimated MAUF, several
scales are proposed to be completed by all the patients. TheMont-
gomery-Asberg Depression Rating Scale (MADRS) [14] is a 10-item
(7 levels: 0 to 6) scale measuring the severity of depressive epi-
sodes in patients with mood disorders. The Positive and Negative
Symptoms of Schizophrenia Scale (PANSS) [15] is a 30-item (7 lev-
els: 1 to 7) scale assessing symptom severity of patients with
schizophrenia. The Udvalg for Kliniske Undersogelser (UKU) [16]
scale is designed to evaluate the adverse effects in patients treated
with psychotropic medications. Although the original UKU scale
includes 55 items, a modified 29-item (4 levels: 0 to 3) UKU [17]
scale is considered in this investigation. The Young Mania Rating
Scale (YMRS) [18] is an 11-item (several levels) scalemeasuring the
severity of manic episodes in patients with bipolar disorder. The
Clinical Global Impression Severity (CGIS) scale is a 1-item (7 lev-
els: 1 to 7) scale evaluating the severity of the syndrome from the
clinician’s perspective. The higher that the MADRS, PANSS, UKU,
YMRS, and CGIS scores are, the greater is the severity or the ad-
verse effects associatedwith the disorder. The EQ-5D [19] scale is a
escriptive 5-item (3 levels: 1 to 3) system of generic HRQoL states.
he Short Form-6D (SF-6D) [20] scale is a 6-item (several levels)
lassification system also describing generic HRQoL. The higher
hat the EQ-5D and SF-6D scores are, the better the HRQoL re-
orted by the patient. Because SF-6D Spanish social values are still
ot available and following the methodology proposed by Prieto
nd Sacristan [21], a nonweighted scoring rule based solely on the
nswers provided by the patients to both the SF-6D and the EQ-5D
uestionnaires was considered, thus eliminating the possible influ-
nce that social preferences may have on the scores. The non-
eighted scores were also linearly transformed to the same scale as
hat of the weighted ones. The Pearson correlation coefficients be-
ween the weighted and the nonweighted scores were SF-6D (0.94,
 0.01, UK social values) and EQ-5D (0.98, P  0.01, Spanish social
alues), meaning that the nonweighted approach is enough to ex-
lain the high proportion of the variance in the scores obtained
hrough the use of social values.
Sample design
To detect clinically relevant differences (0.1 points) in mean utili-
ties between two independent groups (t test,   5%, 1-  90%,
two tailed), the required sample size was set at 175 patients. Based
on the previous experience, it was expected that 30% of the se-
lected patients would not be able to successfully complete all the
proposed rating exercises, so a final sample of 250 patients diag-
nosed with schizophrenia (n  125) or bipolar disorder (n  125)
were selected from 50 Spanish public psychiatric centers by 58
clinicians. Each clinician collected data on two patients from each
group, ensuring the designed balance. Ten percent of these pa-
tients were intended to complete all the rating exercises over
again approximately 2 weeks after the first visit, to assess the
test-retest reliability of the utility estimates. After the fieldwork
phase of the study, the collected sample included 243 (test) and 19
(retest) patients.
To be included (or excluded) in the study, patients had to meet
the following criteria:
y Inclusion criteria: willingness to participate in the study
(signed informed consent form), 18 years old or older, diagno-
sis of schizophrenia or bipolar disorders according to the Diag-nostic and Statistical Manual, Fourth Edition, receiving treatment
with antipsychotic medication on a stable dose since at least
the last month, ability to complete all the study procedures.
y Exclusion criteria: presence of adverse effects from any treat-
ment other than antipsychotic drugs, having taken part in a
clinical trial in the past 6 months.
All the scales and ratings proposed in the study were adminis-
tered by the participant clinicians at the selected centers. Before
the data collection stage, specialized personnel individually
trained each clinician (training sessions lasted from 30minutes to
1 hour approximately) on the way in which scales and ratings
should be completed.
Data validation process
As stated, the estimation of theMAUFparameters involved anum-
ber of VAS and TTO ratings of different health states defined from
the items on the TooL questionnaire. Such ratings proved very
difficult to be performed by the patients in the practice.
A careful process of data validation was carried out to ensure
the consistency of the VAS and TTO ratings obtained from the
selected sample. A very conservative approach was followed be-
cause only patients successfully completing all the ratings pro-
posed were considered in terms of the MAUF estimation. Regard-
ing the 16 Single-Attribute Value Functions (SAVFs), 73 of 243 (test)
and 10 of 19 (retest) patients were excluded from the analysis
because they presented either missing or incorrect (out of
range) values (46–49 patients, depending on the domain and
level considered) or they were considered as value reversals
(7–16 patients). Regarding the 12 multiattribute value functions,
137 of 243 and 7 of 19 patients presented either missing data or
invalid responses (6–8 patients, depending on the state consid-
ered) or they were considered as value reversals with respect to
states W (17–32 patients), P (17–30), and H (48–103). Note that
corner state H is directly comparable to states J1 and J2. Regard-
ing the TTO ratings, 3 of 243 and 6 of 19 patients presented
missing values (33–39, depending on the state considered).
The analysis subsample was therefore reduced to the 70 (test)
and 4 (retest) patients successfully completing all the ratings pro-
posed. Regarding the demographic and clinical variables, no sta-
tistically significant differences (P 0.05) were found between the
patients included in the analysis subsample and the patients ex-
cluded from the analysis. Summary statistics for both groups are
presented in Table 3. The analysis subsample is still balanced,
including 52.17% schizophrenic patients, 63.77% were men, the
average (SD) age was 41.88 (11.09) years, and the average (SD) clin-
ical severity was 3.36 (1.18).
Both the statistical package Stata 10 (StataCorp) and the
spreadsheet Excel 2007 (Microsoft) were used to conduct the anal-
yses presented in the Results section.
Results
Table 4 shows the SAVFs estimated fromour data. These functions
were computed as the mean of the VAS ratings within each TooL
domain and level, considering that the rest of domains remained
constant. Table 4 also shows the SAUFs, which were calculated
from the SAVFs by using Equation 4. The alpha coefficient was
estimated as 0.92 by ordinary least squares (OLS) regression (alpha
significance t test P  0.01, R2 .97), after transforming Equation 4
into the linear form described in Equation 5 (values were previ-
ously rescaled into a 0 to 1 scale). A Wald test indicated that the
alpha coefficient was not significantly different from 1 (P  0.48),
meaning that we observe almost a linear relationship between
values and utilities in our data set.
Table 5 shows the VAS and TTO ratings and the estimated
utilities for themultiattribute health states defined in Table 2. The
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569V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 6 4 – 5 7 0constant c is found by numerically solving Equation 3. c  0.99,
eaning that the attributes from the TooL questionnaire are com-
lements. The final coefficients of the MAUF were estimated from
quation 2 and are presented in Table 6. After that, the utility
cores for each individual patient were computed.
Table 7 shows the Spearman correlation coefficients between
he estimated utilities and the rest of scales considered. All corre-
ation coefficients presented the expected signs and were statisti-
ally significant at the 95% confidence level. Good convergent va-
idity was demonstrated because the estimated utilities presented
trong correlations with utilities from the generic HRQoL instru-
ents: EQ-5D (0.69, P .01) and SF-6D (0.66, P 0.01); andmoderate
correlationswith the rest of instruments included: PANSS (0.27, P
0.10), YMRS (0.30, P  0.08), MADRS (0.48, P  0.01), and UKU
0.35, P 0.01).
Criterion validity was also met because significantly higher
tilities were observed for the less severe patients (CGIS scale
core ranging from 1 to 3), according to a Mann-Whitney test (0.49
s. 0.34; P .01). Interestingly, utilities from the MAUF covered a
ider range of health states [0.04,1.00] than those from EQ-5D
0.23,0.96] and SF-6D [0.53,1.00] because the TooL questionnaire is
specific instrument (Figs. 1 and 2).
Unfortunately, it was not possible to assess the test-retest re-
iability of the utility estimates due to the decreased number of
atients successfully completing the second (retest) visit tasks.
Discussion and conclusions
In the current study, a MAUF assessing the impact of the adverse
effects of antipsychotic drugs on patient health utilities was de-
veloped based on a new and specific health state classification
system for patients diagnosed with schizophrenia or bipolar dis-
order, the Spanish version of the TooL questionnaire.
Utilities obtained from the MAUF showed good convergent va-
lidity because they presented strong correlations with utilities
from other generic HRQoL instruments andmoderate correlations
with instruments assessing the severity of the disorders and the
presence of side effects. Because schizophrenia and bipolar disor-
der are chronic diseases, adherence and compliance to treatment
are of major importance. A limitation of this study is that no in-
strument measuring these constructs has been considered with
regard to theMAUF convergent validity. Criterion validitywas also
met because significant differences in mean utilities by clinical
severity were observed. Utilities from the MAUF also covered a
wider range of health states than utilities from EQ-5D and SF-6D,
serving as a complement to generic utilities because they incorpo-
Fig. 1 – SF-6D and TooL utilities.rate the perceptions of the patient.As a drawback, the estimation of the MAUF involved a number
of VAS and TTO ratings, which proved very difficult to be per-
formed by the patients, even though specialized personnel indi-
vidually trained all the participant clinicians to assist the patients
when necessary. The elicitation of preferences always involves
the difficult task of evaluating hypothetical health states. More-
over, the TooL questionnaire was mainly designed on the basis of
the opinions of clinicians, possibly disregarding some aspects of
HRQoL that are relevant from the patients’ perspective.
Regarding the data validation process, a very conservative ap-
proach was followed because only patients successfully complet-
ing all the exercises were included in the analysis subsample. As a
consequence, a considerable amount of the patients from the ini-
tial sample (173 of 243 patients) were not included in the analysis,
and the assessment of the test-retest reliability of the estimated
MAUF was not feasible to perform. Although no statistically sig-
nificant differences were found between the patients included in
the analysis subsample and the patients excluded from the anal-
ysis, further research might extend the findings obtained in here
and cautious conclusions need to be drawn from our results.
Apositive significantandalmost linear relationship (alpha0.92)
was found between values (VAS ratings) and utilities (TTO ratings),
contrary to previous studies in which a concave relationship was
demonstrated (alpha 1) [7,8,10]. This resultmight be due to the fact
hat the alpha coefficient was estimated only considering four data
oints (which reflect the mean patient value-utility combinations),
o the slope of the estimated regressionwas highly sensitive to even
elatively small data point moves.
Additive independence appears to be inadequate in this case
ecause the sum of cj parameters for the utility model is 3.81,
uch greater than 1. This result strongly supports the multiplica-
ive-formapproach chosen. Additionally, attributes can be consid-
red as preference complements because parameter c is equal to
0.99. That means that an improvement on any one attribute
lone is not particularly satisfying, whereas a simultaneous im-
rovement on several attributes is much better, which is also con-
istent with the findings of previous studies [7,8,10,22].
As stated, specific health utilities from the MAUF also covered
wider range of health states than those fromother generic health
nstruments included (EQ-5D and SF-6D). This point raises the is-
ue on using either generic or specific health utilities as a decision
ool. Another related debate is whether preference measures
hould be directly elicited from the patient’s view or from a gen-
ral population perspective. On the one hand, patients have direct
xperience of the disease and should be able to provide more in-
ormed responses as to the burden of the health states that they
ave experienced. On the other hand, individuals from the general
opulation have no interests in a particular disease and can beFig. 2 – EQ-5D and TooL utilities.
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It is worth noting that, with regard to the economic evaluation,
tilities from the TooL are not intended to replace generic utilities
ut to serve as a complement to the generic instruments in the
valuation of drugs showing similar effectiveness but a different
ide effects profile, incorporating the perception of the patient.
he TooL questionnaire is mainly focused on the assessment of
he impact of side effects on patient HRQoL, and, if applied incor-
ectly, utilities from this instrumentmight favor the positive eval-
ation of drugs showing lower associated side effects rather than
rugs providing other health benefits.
Source of financial support: AstraZeneca Spain.
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